diltiazem

(redirected from Tiazac)
Also found in: Thesaurus, Medical.

dil·ti·a·zem

 (dĭl-tī′ə-zĕm′)
n.
A calcium channel blocker drug, C22H26N2O4S, that acts as a coronary vasodilator and is used in the form of its hydrochloride to treat angina pectoris and hypertension.

[(vaso)dil(ator) + -tiazem, suff. for calcium channel blockers (shortening and alteration of benzothiazepine, class of compounds : benzo- + thi(o)- + az(o)- + ep(oxide) + -ine).]

diltiazem

(dɪlˈtaɪəˌzɛm)
n
(Pharmacology) a benzothiapine and a calcium channel blocker, used to treat angina and arrhythmia
ThesaurusAntonymsRelated WordsSynonymsLegend:
Noun1.diltiazem - a calcium blocker (trade name Cardizem) used in treating hypertension or angina or heart failure
calcium blocker, calcium-channel blocker - any of a class of drugs that block the flow of the electrolyte calcium (either in nerve cell conduction or smooth muscle contraction of the heart); has been used in the treatment of angina or arrhythmia or hypertension or migraine
Translations

diltiazem

n diltiazem m
References in periodicals archive ?
That component includes such medicines as the dermatologic treatment Aldara, the hypertension medication Tiazac and the diabetes drug Glumetza.
18 November 2010 - India-based speciality pharmaceuticals company Sun Pharmaceutical Industries Ltd (BOM: 524715) announced today that the US Food and Drug Administration (FDA) has granted its subsidiary an approval for its Abbreviated New Drug Application (ANDA) to market a generic version of once-a-day Tiazac extended release capsules.
In addition, if combined with Sustiva, the following drugs may require a change in the dose of either Sustiva or the other medicine: Ritadin (ritampin); Sporanox (itraconazole); Nizoral (ketoconazole); calcium-channel blockers (for example, Cardizem, Tiazac, and others); and the cholesterol-lowering medications Lipitor (atorvastatin), Pravachol (pravastatin), and Zocor (simvastatin).
Prior to the events giving rise to the Commission's complaint, Biovail had already triggered a 30-month stay of FDA final approval of Andrx's generic Tiazac product, by commencing an infringement lawsuit against Andrx.